Modulating the NLRP3/IL-1β Axis in Age-Related Atherosclerosis: Natural Products, Molecular Mechanisms, and Translational Perspectives—A Narrative Review
Open Access
- 28 September 2026
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1409
Abstract
Atherosclerosis is an age-related immune-metabolic disease in which lipid retention, endothelial dysfunction, innate immune activation, and vascular remodeling interact over decades. In older adults, inflammaging, mitochondrial dysfunction, defective autophagy/mitophagy, and cellular senescence may lower the threshold for persistent inflammasome activation in the vascular wall. The NLR family pyrin domain containing 3 (NLRP3) inflammasome and interleukin-1β (IL-1β) are central to this process because they convert sterile danger signals, including cholesterol crystals, oxidized lipids, mitochondrial stress, and disturbed flow, into caspase-1 activation, IL-1β and interleukin-18 (IL-18) maturation, pyroptosis, endothelial dysfunction, macrophage activation, and plaque destabilization. Clinical proof-of-concept from IL-1β blockade supports inflammatory targeting in atherosclerotic cardiovascular disease, but direct cytokine inhibition leaves upstream inflammasome-prone states insufficiently addressed. This narrative review synthesizes evidence published from 2010 to 2026, together with older landmark studies, on mechanistic, translational, and clinical links between the NLRP3/IL-1β axis and age-related atherosclerosis. Traditional Chinese medicine-derived formulas and isolated natural compounds are considered because they may modulate upstream priming, mitochondrial reactive oxygen species, autophagy, lipid handling, macrophage polarization, endothelial pyroptosis, and inflammasome-associated cytokine release. However, most data remain preclinical, and translation requires stronger causal validation, chemical standardization, pharmacokinetic characterization, age-relevant models, and systematic safety assessment.Keywords
Funding Information
- Russian Science Foundation (25-74-31017)
This publication has 44 references indexed in Scilit:
- Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023JACC, 2025
- Resibufogenin protects against atherosclerosis in ApoE-/- mice through blocking NLRP3 inflammasome assemblyJournal of Advanced Research, 2025
- Buyang Huanwu Decoction stabilizes atherosclerotic vulnerable plaques by regulating intestinal flora, TLR4-NF-κB-NLRP3 inflammatory pathway and mitophagyPhytomedicine, 2025
- Gentiopicroside Alleviates Atherosclerosis by Suppressing Reactive Oxygen Species-Dependent NLRP3 Inflammasome Activation in Vascular Endothelial Cells via SIRT1/Nrf2 PathwayChinese Journal of Integrative Medicine, 2024
- Guizhitongluo Tablet inhibits atherosclerosis and foam cell formation through regulating Piezo1/NLRP3 mediated macrophage pyroptosisPhytomedicine, 2024
- Integrating network pharmacology and experimental models to identify notoginsenoside R1 ameliorates atherosclerosis by inhibiting macrophage NLRP3 inflammasome activationJournal of Natural Medicines, 2024
- Xinmaikang (XMK) tablets alleviate atherosclerosis by regulating the SREBP2-mediated NLRP3/ASC/Caspase-1 signaling pathwayJournal of Ethnopharmacology, 2023
- Tongxinluo attenuates atherosclerosis by inhibiting ROS/NLRP3/caspase-1-mediated endothelial cell pyroptosisJournal of Ethnopharmacology, 2022
- The NLRP3 inflammasome: activation and regulationTrends in Biochemical Sciences, 2022
- Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)The American Journal of Cardiology, 2010